HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal amino acid sequence 176–191 of human growth hormone, with an additional tyrosine residue added at the N-terminus. This fragment was designed to isolate the lipolytic activity of HGH while removing the growth-promoting, IGF-1-stimulating, and insulin-sensitizing effects associated with the full-length molecule.

The fragment activates the beta-3 adrenergic receptor and stimulates cyclic AMP (cAMP) production in adipocytes, promoting fat oxidation. Unlike full-length HGH, it does not appear to cause insulin resistance or stimulate IGF-1 production at research doses, making it a useful tool for selective adipose tissue metabolism studies.

• Selective adipose tissue lipolysis and beta-3 adrenergic receptor studies
• cAMP-mediated fat oxidation research in adipocytes
• Comparison of HGH fragment vs full-length GH lipolytic activity
• Obesity and body composition research models
• Insulin-sparing fat loss mechanism research
• Isolated C-terminal GH fragment pharmacology

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

HGH fragment 176-191, studied for lipolysis. Typically split into morning and pre-fast doses in research.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.